



Impact Of The Cancer Drug List On Top 30 Cancer Drug Prices In Singapore's Public Healthcare Sector

Shu Mei LEE¹, Choon Kee HENG¹, Kar Yee GAN¹, Yan Teck HO¹, Liang LIN¹, Kwong NG¹

¹Agency for Care Effectiveness (ACE), Ministry of Health, Singapore

Introduction

- In September 2022, the Ministry of Health (MOH) introduced a Cancer Drug List (CDL) of clinically proven and cost-effective cancer treatments.
- This analysis aims to review and quantify the impact of the CDL and value-based pricing (VBP) on the prices of top 30 cancer drugs in Singapore.

Methods



We identified the top 30 cancer drugs (75 formulations) by spending based on IQVIA 2023 data.





We reviewed their ex-manufacturer prices in the public sector before and after CDL implementation.



Pre-CDL price – Post-CDL price X 100%

Pre-CDL price





Cost savings per formulation =

Quantum price X Annual volume dispensed in the public sector

Results

- All 30 drugs were included in the CDL for insurance claims, of which 24 were subsidized.
- An average price reduction of 29 percent was achieved through VBP (63 formulations), translating into cost savings of SGD\$116 million in the first year of CDL implementation (Figure 1).
- The average price reductions were 33 percent for subsidized formulations (n = 54) and 6 percent for non-subsidized formulations (n = 9), respectively (Figure 2).

Figure 1: Cost savings achieved in the first year of CDL implementation following VBP





Figure 2: Average price reduction achieved for top 30 cancer drugs through VBP



Conclusion

- Through the CDL, MOH can negotiate better prices and extend funding for more cancer drugs.
- This has allowed effective cancer treatments to be made accessible and affordable to more patients, while ensuring financial sustainability for the Singapore public healthcare system.

Contact

Agency for Care Effectiveness, Ministry of Health, Singapore

Email: MOH_DAC_Secretariat@moh.gov.sg

Website: https://www.ace-hta.gov.sg